Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
301060 Shanghai Labway Clinical Laboratory
24.120
+0.280+1.17%
YOY
Do not show
Hide blank lines
(Q9)2022/09/30(Q6)2022/06/30(Q3)2022/03/31(FY)2021/12/31
Operating Cash Flow
Goods sale service render cash
60.86% 1.6B 37.60% 854.58M 38.54% 396.22M 9.22% 1.35B
Refunds of taxes and levies
-- -- -- 0 -- -- -- --
Cash received relating to other operating activities
36.30% 21.14M 17.35% 13.2M -19.64% 4.31M 57.16% 24.08M
Cash inflows from operating activities
60.48% 1.62B 37.24% 867.79M 37.47% 400.54M 9.80% 1.38B
Goods services cash paid
44.60% 1.05B 47.50% 658.13M 75.57% 352.22M -7.21% 699.58M
Staff behalf paid
225.20% 529.26M 164.50% 301.9M 71.10% 115.87M 42.59% 246.62M
All taxes paid
152.48% 140.23M 104.30% 80.36M 72.75% 31.44M 19.95% 77.25M
Cash paid relating to other operating activities
23.09% 142.22M 128.86% 99.52M 191.92% 53.15M 37.53% 128.16M
Cash outflows from operating activities
75.62% 1.86B 77.24% 1.14B 81.36% 552.68M 6.19% 1.15B
Net cash flows from operating activities
-366.01% -244.93M -2,413.04% -272.12M -1,036.60% -152.15M 33.14% 223.51M
Investing cash flow
Cash received from disposal of investments
276.96% 701.15M 775.34% 701.15M 632.53% 367M 16.92% 644.1M
Cash received from returns on investments
47.45% 9.51M 148.38% 9.51M 780.15% 4.05M -21.44% 6.88M
Net cash received from disposal of fix assets、 intangible assets 、other long-term asset
150.07% 1.97M -35.80% 1.11M 79.32% 674.32K -30.95% 5.49M
Net cash received from disposal of subsidiaries and other business units
-- -- -- 0 -- -- -- --
Cash received relating to other investing activities
-- -- -- 0 -- -- -- --
Cash inflows from investing activities
268.78% 712.64M 730.99% 711.76M 629.78% 371.73M 15.66% 656.48M
Cash paid to acquire fixed assets intangible assets and other long-term assets
581.89% 185.02M 236.29% 114.51M 90.41% 36.02M 166.86% 118.88M
Cash paid to acquire investments
7.35% 303.96M 11.04% 285.96M 11.95% 287.71M 114.19% 941M
 Net cash paid to acquire subsidiaries and other business units
-- -- -- 0 -- -- -- --
Cash paid relating to other investing activities
-- -- -- 0 -- -- -- --
Cash outflows from investing activities
57.59% 488.99M 37.35% 400.47M 17.33% 323.72M 119.04% 1.06B
Net cash flows from investing activities
291.09% 223.65M 251.17% 311.29M 121.34% 48M -581.85% -403.41M
Financing cash flow
Cash received from capital contributions
-97.69% 3.79M -64.86% 1.79M -84.55% 785K 7,548.69% 166.74M
-Including: Cash received from capital contributions by minority shareholders of subsidiaries
-25.49% 3.79M -64.86% 1.79M -84.55% 785K 275.83% 8.19M
Cash from borrowing
3,668.97% 150.73M 4,972.29% 113M 0.00% 2M -- 4M
Cash received relating to other financing activities
-- 3.84M -- 0 -- -- -- --
Cash inflows from financing activities
-5.53% 158.36M 1,470.72% 114.79M -60.66% 2.79M 7,732.15% 170.74M
Borrowing repayment
799.96% 18M -0.04% 2M -- 2M -- 2M
Dividend interest payment
257,020.28% 123.79M 7,431.11% 120.93M 9.32% 16.04K -60.86% 13.8M
-Including:Cash payments for dividends or profit to minority shareholders
-- -- -- 0 -- -- -- 13.5M
Cash payments relating to other financing activities
-- 15.56M 5.30% 10.73M 20.83% 4.09M -44.17% 35.19M
Cash outflows from financing activities
7,582.17% 157.34M 868.81% 133.66M 79.63% 6.1M -48.12% 50.99M
Net cash flows from financing activities
-99.39% 1.01M -190.91% -18.88M -190.06% -3.32M 224.60% 119.75M
Net cash flow
Exchange rate change effecting cash and cash equivalents
-3,457.20% -455.31K -386.98% -191.48K -123.87% -17.18K 108.17% 19.55K
Net increase in cash and cash equivalents
-416.95% -20.72M 109.01% 20.1M 54.19% -107.48M -138.73% -60.12M
Add:Begin period cash and cash equivalents
-0.20% 351.48M -14.61% 351.48M -14.61% 351.48M 60.56% 411.6M
End period cash equivalent
-5.00% 330.76M 97.20% 371.58M 37.86% 244M -14.61% 351.48M
Currency Unit
CNYCNYCNYCNY
Accounting Standards
CAS (2007)CAS (2007)CAS (2007)CAS (2007)
Audit Opinions
------Unqualified opinion
Auditor
------Rongcheng Accounting firm (Special General Partnership)

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
The company is a high-tech enterprise that provides comprehensive health management solutions relying on medical laboratory and pathological diagnosis services. Through the business model of providing third-party medical diagnostic services and selling in vitro diagnostic products, the company enables medical technology laboratories such as hospital laboratory, pathology department and central laboratory to help them reduce operating costs and operational risks. improve the quality and technical level of medical services. At present, the company's business covers more than ten provinces and cities, and there are more than ten regional medical laboratory and pathological diagnosis centers, forming a brand, large-scale and standardized laboratory network. The company is an integrated service provider providing overall solutions for the inspection and diagnosis industry, providing third-party medical testing and pathological diagnosis services to medical institutions at all levels, selling in vitro diagnostic products of well-known brands at home and abroad and other professional technical support, in order to meet the differentiated needs of medical institutions at all levels. Medical laboratory and pathological diagnosis services, sales of in vitro diagnosis products, medical diagnosis services, etc. Corporate honors: top 100 Shanghai service enterprises in 2019, top 100 private service enterprises in Shanghai, civilized units in Shanghai, etc.
CEO: --
Market: --
Listing Date: 09/13/2021
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist